Studies of nucleotide receptors (P2-receptors) in cells and tissues are com
plicated by cleavage of phosphate groups from nucleotide agonist ligands by
ecto-nucleotidases. Some P2 receptor antagonists may also inhibit ecto-nuc
leotidases, making these studies even more complex. In order to systematica
lly approach this problem, we investigated structure-activity relationships
of pyridoxal-5'-phosphate-6-azophenyl-2,4-disulfonate (PPADS) and 14 deriv
atives, many potent as antagonists at P2 receptors, as inhibitors of ecto-n
ucleotidases. The compounds were tested for their ability to inhibit enzyma
tic nucleotide breakdown by CHO cells stably transfected with plasmids cont
aining the cDNA for rat ecto-apyrase (NTPDase1) and rat ecto-ATPase (NTPDas
e2). All inhibitors were tested at a concentration of 100 muM and ATP hydro
lysis was quantified by HPLC. Maximal inhibition obtained for ecto-apyrase
and ecto-ATPase was 60% and 35%, respectively. Most PPADS analogs were bett
er inhibitors of ecto-apyrase than of ecto-ATPase. Compound 8, a phosphate
derivative, inhibited ecto-apyrase with no inhibition evident at ecto-ATPas
e. Comparison of pharmacological data of PPADS analogs at P2 receptors as p
reviously determined showed that four PPADS analogs exhibited selectivity f
or P2X nucleotide receptors. None of these compounds inhibited ecto-ATPase,
while two inhibited the ecto-apyrase. Compound 14, a bisphosphate derivati
ve, inhibited ecto-ATPase without inhibition of ecto-apyrase. This compound
only weakly antagonized P2X(1) receptors and was inactive at P2X(2) and P2
Y(1) receptors, thus bearing some selectivity for ecto-ATPase. Compound 7,
a 5-methylphosphonate derivative, a potent antagonist of P2X(1) receptors,
was inactive at ecto-apyrase and only weakly inhibitory at ecto-ATPase. Thu
s, PPADS modifications that enhance selectivity among ecto-nucleotidases an
d P2 receptors have been identified. Drug Dev. Res. 51:153-158, 2000. Publi
shed 2001 Wiley-Liss, Inc.